SOURCE: SciClone Pharmaceuticals, Inc.

SciClone Pharmaceuticals, Inc.

September 09, 2009 07:30 ET

SciClone Pharmaceuticals to Present at Two September Investor Conferences

ThinkEquity Annual Growth Conference (G6) on Wednesday, September 16 at 3:15 pm PT; UBS Global Life Sciences Conference on Wednesday, September 23 at 1:30 pm ET

FOSTER CITY, CA--(Marketwire - September 9, 2009) - SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it will present at two upcoming investor conferences: ThinkEquity's Annual Growth Conference (G6) in San Francisco, and the UBS Global Life Sciences Conference in New York City. Friedhelm Blobel, Ph.D., SciClone's President and Chief Executive Officer, will present a corporate overview and business update at each conference.

WHEN:  ThinkEquity Annual Growth Conference (G6)
       Wednesday, September 16; 3:15 pm PT
       San Francisco, CA

WHEN:  UBS Global Life Sciences Conference
       Wednesday, September 23; 1:30 pm ET
       New York, NY

To access the live audio webcasts of the presentations, please log on through a link located in the Investor Relations section of SciClone's website at www.sciclone.com.

About SciClone

SciClone Pharmaceuticals (NASDAQ: SCLN) is a profit-driven, global biopharmaceutical company with a substantial international business and a product portfolio of novel therapies for cancer and infectious diseases. SciClone is focused on continuing international sales growth, a cost-containing clinical development strategy, and expense management. ZADAXIN (thymalfasin or thymosin alpha 1) is sold in over 30 countries for the treatment of hepatitis B (HBV) and hepatitis C (HCV), certain cancers and as a vaccine adjuvant. SciClone's pipeline of drug candidates includes thymalfasin for stage IV melanoma, for which SciClone has reached agreement with the FDA on the design of a phase 3 trial; RP101 in a phase 2 trial for the treatment of pancreatic cancer; SCV-07 in a phase 2 trial for the delay of onset of severe oral mucositis in patients receiving chemoradiation therapy for the treatment of cancers of the head and neck; and SCV-07 with a ready-to-initiate phase 2 trial for the treatment of HCV. SciClone has exclusive commercialization and distribution rights to DC Bead™ in China, where the product is under regulatory review. The Company also has commercialization and distribution rights to an anti-nausea drug ondansetron RapidFilm™ in China and Vietnam, for which it is seeking regulatory approval. For additional information, please visit www.sciclone.com.